New drugs that do not rely on hormones to treat breast cancer can be more efficient

  • Author:Jane
  • Source:medicalxpress
  • Release on :2017-08-10
Researchers at the Simmons Cancer Center in South West have shown that first-line molecules can prevent breast cancer development when traditional therapies are stopped working.

The first-line drug is a drug that acts through a unique mechanism, in this case a molecule that targets the protein on the estrogen receptor of the tumor cell. Potential drugs provide hope for breast cancer patients who have resisted traditional therapies.

"This is a new type of estrogen receptor-positive breast cancer drug whose unique mechanism of action overcomes the limitations of current therapies," said Dr. Ganesh Raj, Ph.D., Professor of Urology at the Harold Simmons Cancer Center in South West. Sex.

Scientists tested all breast cancer to determine if estrogen growth was needed and found that about 80% was sensitive to estrogen. These cancers can usually be treated effectively by hormone therapy, such as tamoxifen, but one third of these can eventually become resistant. Dr. Raj, a member of the Southwest Urology Cancer Group, said the new compounds are a potentially highly effective treatment for these patients and look forward to the next treatment.

Traditional hormonal drugs, such as tamoxifen, prevent estrogen-binding receptors by attaching to molecules called estrogen receptors in cancer cells, which are necessary steps for cancer cell proliferation. But the estrogen receptor can change and shape its shape over time, making the therapeutic agent no longer fully compatible with the receptor. When this happens, the cancer cells begin to multiply again.

"The interest in developing drugs that hinder the interaction of estrogen receptors (the main target of most breast cancers) with the co-regulators that cause tumor growth has been great, preventing this" protein-protein interaction ", Dr. Raj and His colleagues have made remarkable achievements by discovering the first person in a therapeutic drug that can be used to achieve this dream, "said Dr. David Mangelsdorf, professor and director of the Department of Pharmacology. He is the Chairman of the Pharmacology of Alfred Gilman, and Raymond and Ellen Willie Distinguished Professor of Neurogenesis.

The drug works by preventing other molecules and proteins that are synergistic factors (which must also be attached to estrogen receptors to propagate cancer cells) - called new molecular mimetic peptides or protein structural units called ERX-11. So far, cancer cells that have been removed from the patient have been tested in mice and cancer cells and have a good effect in both models, and there are no signs of toxicity in the test.

If it is successfully transformed into human therapy, another advantage of ERX-11 is that it can be administered orally by the patient rather than infusion. Dr. Raj said the group wanted to conduct clinical trials in about a year.

The concept of blocking protein synergistic factors also affects the treatment of other cancers. "This may be a first-line treatment for breast cancer and may even lead to new therapies for other hormone-sensitive cancers, and now it offers hope for women with estrogen-sensitive breast cancer," Dr. Raj said.